1. bookAHEAD OF PRINT
Journal Details
License
Format
Journal
First Published
30 Mar 2015
Publication timeframe
4 times per year
Languages
English
access type Open Access

Characteristics and outcomes of patients with COVID-19 and liver injury: a retrospective analysis and a multicenter experience

Published Online: 12 Jul 2021
Page range: -
Received: 24 May 2021
Journal Details
License
Format
Journal
First Published
30 Mar 2015
Publication timeframe
4 times per year
Languages
English
Abstract

Background and aims: Patients with COVID-19 frequently present abnormal elevated liver function tests of unknown clinical significance. We aimed to investigate the characteristics and factors influencing outcome in patients with confirmed SARS-CoV-2 infection and liver injury on admission.

Methods: This is a retrospective observational study of patients hospitalized in two COVID units in Romania. Relevant data on clinical and laboratory parameters and medication administered during the admission were analyzed to identify predictors of a negative outcome. Patients with confirmed COVID-19 and liver function tests (LFTs) above the upper limit of normal were included in the analysis.

Results: From 1,207 patients, we identified 134 patients (11%) with abnormal LFTs during hospitalization. The majority of patients had mildly elevated levels and a predominantly cholestatic pattern of liver injury. Patients who received lopinavir/ritonavir were more likely to have increased ALAT levels (p<0.0001). Sixteen patients had pre-existing chronic liver disease, and they were more likely to suffer from severe COVID-19 (p=0.009) and have a negative outcome (p<0.001), but on multivariate analysis, only the severity of COVID-19 was predictive of death (OR 69.9; 95% CI 6.4-761.4).

Conclusions: Mild liver injury is relatively common in COVID-19 and possibly influenced by medication. Patients with chronic liver disease are at high risk for negative outcome, but the severity of the infection is the only predictor of death.

Keywords

1. CICHOŻ-LACH H., MICHALAK A. Liver injury in the era of COVID-19. World journal of gastroenterology 2021;27(5): 377.Search in Google Scholar

2. DONG ZY, et al. The prevalence of gastrointestinal symptoms, abnormal liver function, digestive system disease and liver disease in COVID-19 infection: a systematic review and meta-analysis. Journal of Clinical Gastroenterology 2021; 55(1): 67.Search in Google Scholar

3. KUNUTSOR SK., LAUKKANEN JA. Markers of liver injury and clinical outcomes in COVID-19 patients: a systematic review and meta-analysis. Journal of Infection 2021; 82(1): 159-198.Search in Google Scholar

4. NARDO AD, et al. Pathophysiological mechanisms of liver injury in COVID- 19. Liver International 2021; 41(1): 20-32.Search in Google Scholar

5. JOTHIMANI D, VENUGOPAL R, ABEDIN MF, KALIAMOORTHY I, RELA M. COVID-19 and Liver [published online ahead of print, 2020 Jun 15]. J Hepatol. 2020; S0168-8278(20)30377-9.Search in Google Scholar

6. https://www.covid-hep.net/Search in Google Scholar

7. ALQAHTANI SA, SCHATTENBERG JM. Liver injury in COVID-19: The current evidence. United European Gastroenterol J. 2020;8(5):509-519.Search in Google Scholar

8. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; Clinical Practice Guideline Panel: Chair; Panel members; EASL Governing Board representative: EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol. 2019 Jun;70(6):1222-1261Search in Google Scholar

9. GARRIDO I, LIBERAL R, MACEDO G. Review article: COVID-19 and liver disease-what we know on 1st May 2020. Aliment Pharmacol Ther. 2020;52(2):267-275. doi:10.1111/apt.15813Search in Google Scholar

10. https://www.ncbi.nlm.nih.gov/books/NBK547961/ [accessed 25 July 2020]Search in Google Scholar

11. https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19 [accessed 25 July 2020]Search in Google Scholar

12. MARJOT, T, et al. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study. J Hep 2021; 74(3): 567-577Search in Google Scholar

13. SHAO, J., et al. Implications of liver injury in risk-stratification and management of patients with COVID-19. Hepatology international (2021): 1-11.Search in Google Scholar

14. SIKKEMA, B. J., NICOLAAS, JS., VAN WIJNGAARDEN P. No association between COVID-19 related liver injury and the course of disease: a retrospective study. Scandinavian Journal of Gastroenterology 2021; 56(1): 68-71.Search in Google Scholar

15. YA-WEN A., et al. Liver function recovery of COVID-19 patients after discharge, a follow-up study. International journal of medical sciences 2021; 18 (1): 176.Search in Google Scholar

16. HAMID S., et al. WGO Guidance for the Care of Patients with COVID-19 and Liver Disease. Journal of Clinical Gastroenterology 2021; 55 (1): 1.Search in Google Scholar

17. ZHANG C, SHI L, WANG FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020;5(5):428-430.Search in Google Scholar

18. https://www.who.int/publications/i/item/clinical-management-of-covid-19Search in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo